Previous 10 | Next 10 |
Gainers: BBQ Holdings ( BBQ ) +46% . Verona Pharma ( VRNA ) +41% . Mersana Therapeutics ( MRSN ) +31% . SAI.TECH Global ( SAI ) +30% . Atara Biotherapeutics ( ATRA ) +28% . PubMatic ( PUBM ) +24% . RumbleON ( RM...
Atara Biotherapeutics ( NASDAQ: ATRA ) stock rose ~27% on Aug. 9 after the company's Q2 results beat analysts' estimates and the CEO said that the FDA recommended a possible path towards a regulatory filing for tabelecleucel (tab-cel) without the need for a new clinical ...
Gainers: Verona Pharma VRNA +87% . Mersana Therapeutics ( MRSN ) +38% . GoodRx Holdings ( GDRX ) +19% . Atara Biotherapeutics ( ATRA ) +22% . Heron Therapeutics HRTX +16% . Losers: CorMedix ( CRMD ) -56% . Qu...
Atara Biotherapeutics, Inc. (ATRA) Q2 2022 Earnings Conference Call August 08, 2022, 04:30 PM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Utpal Koppikar - CFO Jakob Dupont - EVP and Global Head of Research...
Atara Biotherapeutics press release ( NASDAQ: ATRA ): Q2 GAAP EPS of $0.18 beats by $1.14 . Revenue of $51.58M (+1232.8% Y/Y) beats by $45.05M . Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets ATA188 Phase...
Atara to Focus on R&D Activities Prioritizing Upcoming Milestones for Key Pipeline Assets ATA188 Phase 2 EMBOLD Study Interim Analysis Completed with Target Enrollment Achieved; Primary Endpoint Data Read Out Planned for October 2023 FDA Recommended Pathway to Pote...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President...
Live Conference Call and Webcast at 4:30 p.m. EDT Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoi...
Atara Biotherapeutics ( NASDAQ: ATRA ) has lost ~4% in the pre-market Wednesday after Bank of America downgraded the stock issuing the only Sell rating for the clinical-stage biotech on the Street. The analysts led by Yigal Nochomovitz attribute their bearish view to Pha...
Vascular Biogenics ( VBLT ) -78% after late-stage trial for ovarian cancer treatment fails ; cut to Neutral at HC Wainwright after trial failure sinks stock 79%. Adial Pharmaceuticals ( ADIL ) -28% as AD04 fails to best placebo in very heavy drinkers in t...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...